Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 94.10M P/E 60.00 EPS this Y 25.00% Ern Qtrly Grth -
Income 7.73M Forward P/E 20.00 EPS next Y 60.00% 50D Avg Chg -25.00%
Sales 53.61M PEG - EPS past 5Y -20.63% 200D Avg Chg -39.00%
Dividend N/A Price/Book 5.84 EPS next 5Y - 52W High Chg -55.00%
Recommedations 1.50 Quick Ratio 0.38 Shares Outstanding 53.14M 52W Low Chg 1.00%
Insider Own 38.65% ROA 0.34% Shares Float 26.84M Beta 0.97
Inst Own 30.13% ROE 35.65% Shares Shorted/Prior 398.20K/434.43K Price 1.80
Gross Margin 52.22% Profit Margin 14.42% Avg. Volume 211,709 Target Price 6.81
Oper. Margin 0.88% Earnings Date Nov 5 Volume 268,164 Change -4.26%
About Paysign, Inc.

Paysign, Inc. provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card. The company markets its prepaid card solutions under the Paysign brand. Its primary market focus is on companies and municipalities that require a streamlined payment solution for rewards, rebates, payment assistance, and other payments to their customers, employees, agents, and others. The company was formerly known as 3PEA International, Inc. and changed its name to Paysign, Inc. in April 2019. Paysign, Inc. was incorporated in 1995 and is headquartered in Henderson, Nevada.

Paysign, Inc. News
11/08/24 Earnings Beat: Paysign, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
11/06/24 3 US Penny Stocks With Market Caps Up To $400M
11/06/24 PaySign Inc (PAYS) Q3 2024 Earnings Call Highlights: Impressive Revenue Growth and Strategic ...
11/05/24 Paysign, Inc. Reports Third Quarter 2024 Financial Results
10/15/24 Paysign to Host Third Quarter 2024 Earnings Call
10/04/24 Paysign (NASDAQ:PAYS) shareholders YoY returns are lagging the company's 488% one-year earnings growth
08/08/24 Paysign, Inc. to Participate in the August 2024 Sidoti Micro-Cap Virtual Conference
08/07/24 Paysign, Inc. to Present at the Oppenheimer Technology, Internet & Communications Conference
08/02/24 Analysts Have Made A Financial Statement On Paysign, Inc.'s (NASDAQ:PAYS) Second-Quarter Report
07/31/24 Paysign, Inc. Reports Second Quarter 2024 Financial Results
07/09/24 Paysign to Host Second Quarter 2024 Earnings Call
07/02/24 Paysign, Inc. (NASDAQ:PAYS) boasts of bullish insider sentiment with 39% ownership and they have been buying lately
06/20/24 Paysign, Inc. to Participate in the 2024 Maxim Fintech Virtual Symposium, June 25
06/18/24 Paysign, Inc. to Participate in the 2024 iAccess Alpha Buyside Best Ideas Summer Conference
06/11/24 Sidoti Events, LLC's Virtual June Small-Cap Conference
06/06/24 Paysign, Inc. to Participate in the June 2024 Sidoti Small-Cap Virtual Investor Conference
06/05/24 Is Now The Time To Put Paysign (NASDAQ:PAYS) On Your Watchlist?
05/09/24 Paysign, Inc. Just Beat Revenue By 6.0%: Here's What Analysts Think Will Happen Next
05/07/24 PaySign Inc (PAYS) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance
05/07/24 Paysign, Inc. Reports First Quarter 2024 Financial Results
PAYS Chatroom

User Image 11thestate Posted - 2 days ago

$PAYS is accepting claims for a $3.75M settlement it is paying to investors over setbacks in Paysign’s internal control over financial reporting. Even if the deadline has passed, if you bought between March 12, 2019, and March 31, 2020, you can still file for payment here: https://11thestate.com/cases/paysign-shareholder-settlement

User Image Jpike55 Posted - 4 days ago

$PAYS Yesterday CEO finished selling his 100,000 shares per filing this morning.

User Image Jpike55 Posted - 4 days ago

$PAYS Bottom in. It UP from here.

User Image Stockpooper30 Posted - 5 days ago

$PAYS ANOTHER DAY DOWN WTF - THEY NEED TO DO SOMETHING WITH THIS

User Image odys3131 Posted - 6 days ago

$PAYS What is happening?

User Image nyamsamb Posted - 1 week ago

$PAYS Doubled at 3.39$. Next buy is 3$.

User Image Jpike55 Posted - 1 week ago

$PAYS cheaper every day....ridiculous.

User Image nyamsamb Posted - 1 week ago

$PAYS Did not buy. 3.52$ is broken. Will wait.

User Image nyamsamb Posted - 1 week ago

$PAYS Added at 3.59$. Will add at 3.53$.

User Image nyamsamb Posted - 1 week ago

$PAYS Increased 25% in 3.63$. But really, would like to buy in low 3$. Insiders were willing to sell in 3.6$ lately.

User Image Jpike55 Posted - 1 week ago

$PAYS CEO and officers appear to be benefiting themselves and NOT the shareholders by selling their shares monthly in large amounts. Easy fix is sell this profitable growing company to big pharma NOW. Monthly selling of shares is horrendous...just look at the chart!!! UGLY.

User Image Jpike55 Posted - 1 week ago

$PAYS Perhaps they used it to buy the free shares that officers were selling ???

User Image daviddsp Posted - 1 week ago

$PAYS Question at the end of June 24 PAYS had $31mil cash, now only $10mil cash, where did the money go? Anyone know? Thanks

User Image nyamsamb Posted - 2 weeks ago

$PAYS Insider sell?

User Image BuyOnRedSellOnGreen Posted - 2 weeks ago

$PAYS adding here

User Image nyamsamb Posted - 2 weeks ago

$PAYS Holding tight. Tired of early locking.

User Image erevnon Posted - 2 weeks ago

Barrington Research maintains PaySign $PAYS at Outperform and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image BuyOnRedSellOnGreen Posted - 2 weeks ago

$PAYS even with the hurricane issues the company continues to execute 👍🏻

User Image DonCorleone77 Posted - 2 weeks ago

$PAYS Paysign affirms FY24 revenue view of $56.5M-$58.5M, consensus $57.5M The company states: "We executed on another positive quarter with year-over-year quarterly revenues increasing 23.0% to $15.26 million and adjusted EBITDA increasing 20.6% to $2.83 million as our pharma patient affordability business continued its growth momentum. Pharma patient affordability revenue equated to 21.5% of total revenues, up from 8.3% of total revenues for the same quarterly period last year. We exited the quarter with 478 plasma centers and 66 pharma patient affordability programs, an increase of 14 and 23, respectively, since the end of 2023. Full-year 2024, pharma patient affordability revenue is on track to equal approximately 20.0% of total revenues. Despite headwinds in our plasma business related to difficult weather conditions, employment conditions and a slowdown in spending by cardholders, we still experienced growth this quarter of 3.4% when compared to the same period in the prior year. The only update to the guidance that we provided during our second-quarter conference call relates to legal fees that we expect to expense during the fourth quarter related to the settlement of our class action and derivative lawsuits as further disclosed in our 10-Q that will be released prior to the market opening tomorrow. This expense was not anticipated at the time we provided financial guidance but we still anticipate our operating results to be within the ranges we provided despite this one-time expense. To reiterate, we expect total revenues to be in the range of $56.5 million to $58.5 million, and adjusted EBITDA to be in the range of $9.0 million to $10.0 million (15.0% to 17.0% of total revenues), or $0.16 to $0.18 per fully diluted share."

User Image DonCorleone77 Posted - 2 weeks ago

$PAYS Paysign reports Q3 EPS 3c, consensus 1c Reports Q3 revenue $15.3M, consensus $14.8M. "We are pleased to report strong third-quarter results, achieving 23.0% revenue growth and a 20.6% increase in adjusted EBITDA," said Mark Newcomer, President & CEO of Paysign. "Revenue from patient affordability programs rose by 219.1% year-over-year, and we ended the quarter with 66 active programs. Gross margins also saw a strong improvement, increasing by 440 basis points to 55.5% compared to third quarter 2023, driven by growth in our higher-margin patient affordability programs. We expect this upward trend to continue. Our patient affordability pipeline remains highly robust as we add new customers, new programs, expand programs and maintain strong relationships with some of the world's leading pharmaceutical companies, further affirming their confidence in our offerings. We are focused on identifying and leveraging additional high-growth opportunities in the payments sector to expand our current product portfolio. As always, we are committed to growing our company and maximizing long-term shareholder value."

User Image BuyOnRedSellOnGreen Posted - 2 weeks ago

$PAYS earnings after the close

User Image nyamsamb Posted - 10/30/24

$PAYS only position. Waiting for this Russel euphoria end.

User Image BuyOnRedSellOnGreen Posted - 1 month ago

$PAYS new long position

User Image insiderbuyingselling Posted - 1 month ago

$PAYS new insider selling: 100000 shares. http://insiderbuyingselling.com/?t=PAYS

User Image nyamsamb Posted - 1 month ago

$PAYS Re-entered.

User Image Jpike55 Posted - 1 month ago

$PAYS Very old news you post often. Good news is the future is profitable on all fronts.

User Image 11thestate Posted - 1 month ago

$PAYS is accepting claims for a $3.75M settlement it is paying to investors over setbacks in Paysign’s internal control over financial reporting. Even if the deadline has passed, if you bought between March 12, 2019, and March 31, 2020, you can still file for payment here: https://11thestate.com/cases/paysign-shareholder-settlement

User Image nyamsamb Posted - 1 month ago

$PAYS Ouch. Did not trim enough yesterday.

User Image StockBoyAri Posted - 1 month ago

$PAYS this feels like it’s about to go. Keep an eye on it. I have firm belief $6+ is due. Just my opinion of course.

User Image nyamsamb Posted - 1 month ago

$PAYS Bought back some of my shares.

Analyst Ratings
Barrington Research Outperform Jun 28, 24
Barrington Research Outperform May 28, 24
Barrington Research Outperform May 10, 24
Maxim Group Buy May 8, 24
Barrington Research Outperform May 6, 24
DA Davidson Buy Apr 30, 24
DA Davidson Buy Apr 1, 24
Barrington Research Outperform Mar 27, 24
DA Davidson Buy Mar 25, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Topline Capital Management, LL... Other Other Feb 02 Buy 2.98 112,300 334,654 3,684,656 02/06/24
Topline Capital Partners, LP 10% Owner 10% Owner Feb 02 Buy 2.98 112,300 334,654 5,684,656 02/06/24
Topline Capital Management, LL... Other Other Jan 29 Buy 2.99 108,327 323,898 5,572,356 01/31/24
Topline Capital Partners, LP 10% Owner 10% Owner Jan 29 Buy 2.99 108,327 323,898 5,572,356 01/31/24
Topline Capital Management, LL... Other Other Jan 23 Buy 2.79 107,157 298,968 5,464,029 01/25/24
Topline Capital Partners, LP 10% Owner 10% Owner Jan 23 Buy 2.79 107,157 298,968 5,464,029 01/25/24
Strobo Robert Chief Legal Officer Chief Legal Officer Oct 31 Sell 1.75 16,709 29,241 175,501 11/02/23
Strobo Robert Chief Legal Officer Chief Legal Officer Oct 31 Option 0 40,000 192,210 11/02/23
Mina Bruce A Director Director Aug 15 Sell 1.9409 780 1,514 217,720 08/28/23
Strobo Robert CLO CLO Aug 03 Sell 1.8 10,067 18,121 152,210 08/07/23
Newcomer Mark CEO CEO Aug 03 Sell 1.8 24,627 44,329 9,468,479 08/07/23
Lanford Matthew Louis COO, President COO, President Aug 03 Sell 1.8 9,974 17,953 88,469 08/07/23
Herman Joan M Director Director Aug 03 Sell 1.8 5,524 9,943 779,597 08/07/23
Baker Jeffery Bradford Chief Financial Offi.. Chief Financial Officer Aug 03 Sell 1.8 12,044 21,679 124,788 08/07/23
Herman Joan M EVP, Operations EVP, Operations Jul 31 Sell 1.85 8,547 15,812 785,121 08/03/23
Herman Joan M EVP, Operations EVP, Operations Jul 31 Option 0 36,000 793,668 08/03/23
Newcomer Mark CEO CEO Jul 31 Option 0 150,000 9,531,202 08/03/23
Newcomer Mark CEO CEO Jul 31 Sell 1.85 38,096 70,478 9,493,106 08/03/23
Baker Jeffery Bradford Chief Financial Offi.. Chief Financial Officer Jul 31 Sell 1.85 18,629 34,464 136,832 08/02/23
Baker Jeffery Bradford Chief Financial Offi.. Chief Financial Officer Jul 31 Option 0 64,000 155,461 08/02/23
Lanford Matthew Louis COO, President COO, President Jul 31 Sell 1.85 15,428 28,542 98,443 08/02/23
Lanford Matthew Louis COO, President COO, President Jul 31 Option 0 64,000 113,871 08/02/23
Strobo Robert CLO CLO Jul 31 Sell 1.85 15,572 28,808 162,277 08/02/23
Strobo Robert CLO CLO Jul 31 Option 0 64,000 177,849 08/02/23
Lanford Matthew Louis COO, President COO, President Jun 30 Sell 2.39 7,725 18,463 49,871 07/05/23
Spence Daniel 10% Owner 10% Owner Mar 27 Sell 3.33 200,000 666,000 9,190,000 04/04/23
Baker Jeffery Bradford Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 3.7 27,232 100,758 91,461 03/02/23
Baker Jeffery Bradford Chief Financial Offi.. Chief Financial Officer Feb 28 Option 3.88 60,000 232,800 118,693 03/02/23
Strobo Robert Chief Legal Officer Chief Legal Officer Nov 03 Sell 2.26 2 5 113,849 11/04/22
Lanford Matthew Louis COO, President COO, President Jul 06 Sell 1.72 6,966 11,982 37,596 07/07/22
Baker Jeffery Bradford Chief Financial Offi.. Chief Financial Officer Feb 28 Option 2.17 60,000 130,200 85,000 03/02/22
Baker Jeffery Bradford Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 2.13 26,307 56,034 58,693 03/02/22
Herman Joan M EVP, Operations EVP, Operations Sep 08 Sell 2.38 76,004 180,890 760,611 09/08/21
Herman Joan M EVP, Operations EVP, Operations Sep 08 Option 2.46 200,000 492,000 836,615 09/08/21